



News Release

TerraBioGen Signs Master License Agreement

Vancouver, Canada, October 26, 2011 – TerraBioGen Technologies Inc. (TSX-V: **TBG**), a developer and marketer of proprietary technologies for the production of organic-based, high-value agricultural products from organic wastes, announces that it has signed a Master License Agreement (“MLA”) for the Middle East.

Under the terms of the Master License Agreement (MLA), the licensee is required to pay a license fee of \$1,250,000 by November 21, 2011 and an additional \$1,250,000 upon completion of a 100 tonne per day (“TPD”) plant, expected to occur in 2013. The Company will also receive royalties from the operation of this plant and any additional plants built over a 40 year period along with sub-licensing fees.

Blair Heffelfinger, President and CEO of TerraBioGen, said “This is the first MLA we have negotiated under our new regional license basis. In addition to the license, our new MLA partner will establish a regional office to facilitate technology transfer, product marketing, sales and customer support. This will ensure efficient market introduction of a quality product and expand our business opportunities. In addition, with the process review announced earlier this year showing that a smaller scale plant such as 100 TPD can be built at a much lower cost and generate an attractive internal return, we believe this will facilitate technology adoption.”

About TerraBioGen

Located in North Vancouver, BC, TerraBioGen Technologies Inc. is committed to research and development to continue to improve the efficiency of its technology and the quality of its agricultural products. It is further committed to developing a world-wide marketing capability to ensure market acceptance of its products.

For more information, please contact:

Blair Heffelfinger
President & CEO
TerraBioGen Technologies Inc.
bheffelfinger@terrabiogen.com
(604) 924-1023 ext 316
(604) 924-1043 fax

Bob Nowell
CFO & Corporate Secretary
TerraBioGen Technologies Inc.
bnowell@terrabiogen.com
(604) 924-1023 ext 306
(604) 924-1043 fax

This news release contains certain statements that may be deemed “forward-looking” statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although TerraBioGen believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of TerraBioGen’s management on the date the statements are made. Except as required by law, TerraBioGen undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. THESE SECURITIES HAVE NOT

BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.